Differential Expression of Vascular Endothelial Growth Factor in Glucocorticoid-related Osteonecrosis of the Femoral Head

Varoga, Deike; Drescher, Wolf; Pufe, M; Groth, Godo; Pufe, Thomas

doi:10.1007/s11999-009-1076-3

Cited by 52 publications

(36 citation statements)

References 32 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both in animal models and in humans, VEGF expression was evaluated in mesenchymal cells from osteonecrotic bone with the common conclusion that VEGF enhances bone forming activity (15, 17, 19). Indeed, the expression of VEGF, assessed in human specimens from late stage ON of the femoral head, showed that osteoblasts from the reactive interface exhibited increased VEGF expression, which the investigators postulated to be a secondary phenomenon in an attempt to stimulate the ingrowth of a reparative blood supply (21). In addition, it was also found that osteoblasts derived from OA femoral heads exhibited down-regulation of VEGF after 24 h of co-incubation with glucocorticoids.…”

Section: Endothelial and Bone Cells The Molecular Basis Of Their Intmentioning

confidence: 99%

Bone Vascularization in Normal and Disease Conditions

Carulli¹,

Innocenti²,

Brandi³

2013

Front. Endocrinol.

View full text Add to dashboard Cite

Bone vasculature is essential for many processes, such as skeletal development and growth, bone modeling and remodeling, and healing processes. Endothelium is an integral part of bone tissue, expressing a physiological paracrine function via growth factors and chemokines release, and interacting with several cellular lines. Alterations of the complex biochemical interactions between vasculature and bone cells may lead to various clinical manifestations. Two different types of pathologies result: a defect or an excess of bone vasculature or endothelium metabolism. Starting from the molecular basis of the interactions between endothelial and bone cells, the Authors present an overview of the recent acquisitions in the physiopathology of the most important clinical patterns, and the modern therapeutic strategies for their treatments.

show abstract

Section: Endothelial and Bone Cells The Molecular Basis Of Their Intmentioning

confidence: 99%

Bone Vascularization in Normal and Disease Conditions

Carulli¹,

Innocenti²,

Brandi³

2013

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…VEGF acts in a paracrine and autocrine manner on endothelial cells as a heparin-binding homodimeric glycoprotein (1). VEGF gene transduction has also been found to promote bone marrow cell and endothelial cell proliferation, and induce lumen formation in vitro (2,3). Therefore, the VEGF gene is considered a plausible biological candidate for ONFH.…”

Section: Introductionmentioning

confidence: 99%

Association between vascular endothelial growth factor gene polymorphisms and the risk of osteonecrosis of the femoral head: Systematic review

Hong

Chen

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

Abstract.Emerging evidence has shown that vascular endothelial growth factor (VEGF) gene polymorphisms are the key initiators that regulate the expression of the VEGF protein, which has a vital role in osteonecrosis of the femoral head (ONFH). The aim of the present study was to investigate whether polymorphisms of the VEGF genes are associated with the occurrence of ONFH. A comprehensive search was performed on MEDLINE, Embase, Web of Science and China National Knowledge Infrastructure databases before June 2015. Meta-analyses were carried out for the VEGF gene -634G/C polymorphisms (single-nucleotide polymorphism with 3 eligible studies). The pooled odds ratios with 95% confidence intervals (CIs) were used to evaluate the strength of the association. All the eligible studies, involving 1,564 individuals, were identified. According to the inclusion criteria, 3 case-control studies were finally included in the meta-analysis. The present meta-analysis indicates that the VEGF gene -634G/C polymorphism [CC+GC vs. GG: Response rate (RR)=0.79; 95% CI, 0.67-0.92; GG vs. GC: RR=0.83; 95% CI, GG vs. CC: RR=0.82; 95% CI,] is associated with the occurrence of ONFH, and the association with the male subgroup (RR=0.78; 95% CI, 0.65-0.94; P=0.009) is more evident. In conclusion, the present meta-analysis suggests that the VEGF gene -634G/C polymorphism has a significant association with ONFH occurrence among the investigated patients (P<0.01).

show abstract

“…In addition, VEGF can directly stimulate endothelial cell proliferation, enhance blood vessel formation, increase vascular permeability, and improve the mineralization of the regenerated bone [Street et al, 2002]. Varoga et al [2009] have shown that the loss of VEGF may play a role in the initial stage of ONFH.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Osteonecrosis of the Femoral Head with VEGF<sub>165</sub> Transgenic Bone Marrow Mesenchymal Stem Cells in Mongrel Dogs

Hang

Wang

Guo

et al. 2011

Cells Tissues Organs

View full text Add to dashboard Cite

We evaluated the efficacy of vascular endothelial growth factor 165 (VEGF₁₆₅) transgenic bone marrow mesenchymal stem cells (BMSCs) for the repair of early-stage osteonecrosis of the femoral head (ONFH) in mature mongrel dogs. This animal model was surgically established by femoral neck osteotomy and subsequent repinning. Twenty-seven dogs (54 hips) were divided into 3 equal-sized groups: a pCI-neo-VEGF₁₆₅ BMSC group, a pCI-neo BMSC group and a core decompression-alone group. The lipofectamine was used to introduce the VEGF₁₆₅ gene into the BMSCs. After core decompression, transgenic and non-transgenic autologous BMSCs were implanted. Therapeutic efficacy, including new bone formation and neovascularization in the femoral head, was examined by computed radiography, single-photon emission computed tomography, histological and histomorphometric analysis and immunofluorescent staining for von Willebrand factor in pathological sections. The femoral osteotomy site healed completely by the 4th week after the osteotomy surgery and regions of histologically evident osteonecrosis were found 12 weeks later. A regular arrangement of trabeculae and obvious bone regeneration were observed in the animals receiving implanted VEGF-transgenic BMSCs. The quantity of newly generated capillaries was significantly increased in the pCI-neo-VEGF₁₆₅ BMSC group, but there was no significant difference between the pCI-neo BMSC group and the core decompression-alone group. These results demonstrated that VEGF₁₆₅ transgenic autologous BMSCs enhanced bone reconstruction and blood vessel regeneration in the ONFH model. Compared with non-transgenic BMSCs, this approach could provide advanced benefits in the treatment of ONFH.

show abstract

Differential Expression of Vascular Endothelial Growth Factor in Glucocorticoid-related Osteonecrosis of the Femoral Head

Abstract: VEGF plays a role in bone remodeling.

Cited by 52 publications

References 32 publications

Bone Vascularization in Normal and Disease Conditions

Bone Vascularization in Normal and Disease Conditions

Association between vascular endothelial growth factor gene polymorphisms and the risk of osteonecrosis of the femoral head: Systematic review

Treatment of Osteonecrosis of the Femoral Head with VEGF<sub>165</sub> Transgenic Bone Marrow Mesenchymal Stem Cells in Mongrel Dogs

Contact Info

Product

Resources

About